EU's Advisory Panel Clears MedImmune's Nasal Flu Vaccine; Restricts Use Of Fibrates
This article was originally published in The Pink Sheet Daily
Executive SummaryEurope's top advisory panel, CHMP, issues positive opinions on MedImmune's Fluenz, Lucentis in diabetic macular edema, Sprycel as first-line CML therapy, and Sutent in pancreatic cancer.
You may also be interested in...
Top-line Phase II results from the PULSAR study suggest Acceleron’s sotatercept is effective as add-on treatment for patients with PAH, and could be a new class of therapy for a still difficult-to-control condition.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
A group of Belgian and South Korean investors are providing series B funding to support an early-stage clinical study of an off-the-shelf cancer immunotherapy candidate based on an allogeneic plasmacytoid dendritic cell line.